BridgeBio Pharma, Inc. — Director's Dealing 2025

Aug 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-08-05

Reporting Person: Ellis Andrea (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-05	Common Stock	M	17167	$16.75	Acquired	35756	Direct
2025-08-05	Common Stock	S	17167	$49	Disposed	18589	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-05	Stock Option (right to buy)	$16.75	M	17167	Disposed	2033-06-21	Common Stock (17167)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 30, 2024.

F2: The option vests in three annual installments from June 21, 2024 through June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors.